Product Code: 138172-01-23
An immunoassay is a bioanalytical method used to detect or measure specific proteins or other substances through their properties as antigens or antibodies. A radioimmunoassay (RIA) is an immunoassay that uses an antigen labeled with a radioisotope and measure the subsequent radioactivity of the antibody component in order to detect the antigen-antibody complex. RIA is gaining noteworthy significance in medical diagnostics owing to its high precision, accuracy, specificity of results, and sensitivity. RIA kits are used to perform in-vitro assays/procedures whereas, radioimmunoassay analyzer is a device used to run immunoassay tests in order to detect the presence & concentration of substances in the samples.
The use of radioimmunoassay technique in medical research to find small molecules in the blood and in the clinical diagnosis of cancer, autoimmune diseases, infectious diseases, endocrine disorders, and allergic diseases are majorly driving the growth of the radioimmunoassay market. Technological advances in RIA products coupled with rising adoption of RIA in clinical laboratories, pharmaceutical industries, and research institutes are fostering the market growth rapidly. Moreover, rapid developments in medical research and increased spending in research & development in the healthcare sector to support the market growth in near future. On the contrary, the presence of alternatives to RIA such as ELISA (enzyme-linked immunosorbent assay), chemiluminescent immunoassay (CLIA), immunofluorescence assay (IFA), are anticipated to hinder the market growth over the forecast period.
The reagents & kits segment is expected to dominate the market during the forecast period owing to their limited durability and repetitive purchase or use. The clinical diagnosis segment is likely to register lucrative CAGR over the forecast period owing to worldwide rising prevalence of cancer, autoimmune diseases, infectious diseases, endocrine disorders, and allergic diseases. On the basis of end user, the medical laboratories segment is anticipated to exhibit profitable market growth over next nine years is attributed to rising demand to perform diagnostic procedures.
Europe is likely to hold a major chunk of the market due to higher adoption of radioimmunoassay technique in medical laboratories, pharmaceutical companies and research institutes coupled with flourishing pharmaceutical industries in the U.K., Germany, France, Italy, and Spain. Asia Pacific shall register fastest market growth attributed to growing geriatric population and rising incidence of cancer along with propelled demand for RAI in China and India.
Key players identified in the global radioimmunoassay market include:
PerkinElmer Inc.
Beckman Coulter, Inc.
DIAsource ImmunoAssays SA
Euro Diagnostica AB
Merck KGaA
MP Biomedicals, LLC
DiaSorin S.p.A.
Berthold Technologies GmbH & Co. KG
DRG International, Inc.
STRATEC Biomedical AG
IBL Internationa
Cisbi
EMD Millipore
Izotop
Historical & Forecast Period
This study report represents analysis of each segment from 2021 to 2031 considering 2022 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2023 to 2031.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Radioimmunoassay market are as follows:
Research and development budgets of manufacturers and government spending
Revenues of key companies in the market segment
Number of end users and consumption volume, price and value.
Geographical revenues generate by countries considered in the report:
Micro and macro environment factors that are currently influencing the Radioimmunoassay market and their expected impact during the forecast period.
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.
Market Segmentation
Product
Reagents & Kits
Analyzers
Application
Medical Research
Clinical Diagnosis
End User
Hospitals
Pharmaceutical Companies
Academic Research Institutes
Medical Laboratories
Others
Region Segment (2021-2031; US$ Million)
North America
U.S.
Canada
Rest of North America
UK and European Union
UK
Germany
Spain
Italy
France
Rest of Europe
Asia Pacific
China
Japan
India
Australia
South Korea
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East and Africa
GCC
Africa
Rest of Middle East and Africa
Global Impact of COVID-19 Segment (2020-2021; US$ Million )
Pre COVID-19 situation
Post COVID-19 situation
Key questions answered in this report:
What are the key micro and macro environmental factors that are impacting the growth of Radioimmunoassay market?
What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
Estimated forecast and market projections up to 2031.
Which segment accounts for the fastest CAGR during the forecast period?
Which market segment holds a larger market share and why?
Are low and middle-income economies investing in the Radioimmunoassay market?
Which is the largest regional market for Radioimmunoassay market?
What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
Which are the key trends driving Radioimmunoassay market growth?
Who are the key competitors and what are their key strategies to enhance their market presence in the Radioimmunoassay market worldwide?
Table of Contents
1. Preface
- 1.1. Report Description
- 1.1.1. Purpose of the Report
- 1.1.2. Target Audience
- 1.1.3. Key Offerings
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.3.1. Phase I - Secondary Research
- 1.3.2. Phase II - Primary Research
- 1.3.3. Phase III - Expert Panel Review
- 1.3.4. Assumptions
- 1.3.5. Approach Adopted
2. Executive Summary
- 2.1. Market Snapshot: Global Radioimmunoassay Market
- 2.2. Global Radioimmunoassay Market, By Product, 2021 (US$ Million)
- 2.3. Global Radioimmunoassay Market, By Application, 2021 (US$ Million)
- 2.4. Global Radioimmunoassay Market, By End User, 2021 (US$ Million)
- 2.5. Global Radioimmunoassay Market, By Geography, 2021 (US$ Million)
- 2.6. Attractive Investment Proposition by Geography, 2021
3. Radioimmunoassay Market: Competitive Analysis
- 3.1. Market Positioning of Key Radioimmunoassay Market Vendors
- 3.2. Strategies Adopted by Radioimmunoassay Market Vendors
- 3.3. Key Industry Strategies
- 3.4. Tier Analysis 2021 Versus 2030
4. Radioimmunoassay Market: Macro Analysis & Market Dynamics
- 4.1. Introduction
- 4.2. Global Radioimmunoassay Market Value, 2020 - 2030, (US$ Million)
- 4.3. Market Dynamics
- 4.3.1. Market Drivers
- 4.3.2. Market Restraints
- 4.3.3. Key Challenges
- 4.3.4. Key Opportunities
- 4.4. Impact Analysis of Drivers and Restraints
- 4.5. See-Saw Analysis
5. Radioimmunoassay Market: By Product, 2020-2030, USD (Million)
- 5.1. Market Overview
- 5.2. Growth & Revenue Analysis: 2021 Versus 2030
- 5.3. Market Segmentation
- 5.3.1. Reagents & Kits
- 5.3.2. Analyzers
6. Radioimmunoassay Market: By Application, 2020-2030, USD (Million)
- 6.1. Market Overview
- 6.2. Growth & Revenue Analysis: 2021 Versus 2030
- 6.3. Market Segmentation
- 6.3.1. Medical Research
- 6.3.2. Clinical Diagnosis
7. Radioimmunoassay Market: By End User, 2020-2030, USD (Million)
- 7.1. Market Overview
- 7.2. Growth & Revenue Analysis: 2021 Versus 2030
- 7.3. Market Segmentation
- 7.3.1. Hospitals
- 7.3.2. Pharmaceutical Companies
- 7.3.3. Academic Research Institutes
- 7.3.4. Medical Laboratories
- 7.3.5. Others
8. North America Radioimmunoassay Market, 2020-2030, USD (Million)
- 8.1. Market Overview
- 8.2. Radioimmunoassay Market: By Product, 2020-2030, USD (Million)
- 8.3. Radioimmunoassay Market: By Application, 2020-2030, USD (Million)
- 8.4. Radioimmunoassay Market: By End User, 2020-2030, USD (Million)
- 8.5.Radioimmunoassay Market: By Region, 2020-2030, USD (Million)
- 8.5.1.North America
- 8.5.1.1. U.S.
- 8.5.1.1.1. Radioimmunoassay Market: By Product, 2020-2030, USD (Million)
- 8.5.1.1.1. Radioimmunoassay Market: By Application, 2020-2030, USD (Million)
- 8.5.1.1.1. Radioimmunoassay Market: By End User, 2020-2030, USD (Million)
- 8.5.1.2. Canada
- 8.5.1.2.1. Radioimmunoassay Market: By Product, 2020-2030, USD (Million)
- 8.5.1.2.1. Radioimmunoassay Market: By Application, 2020-2030, USD (Million)
- 8.5.1.2.1. Radioimmunoassay Market: By End User, 2020-2030, USD (Million)
- 8.5.1.3. Rest of North America
- 8.5.1.3.1. Radioimmunoassay Market: By Product, 2020-2030, USD (Million)
- 8.5.1.3.1. Radioimmunoassay Market: By Application, 2020-2030, USD (Million)
- 8.5.1.3.1. Radioimmunoassay Market: By End User, 2020-2030, USD (Million)
9. UK and European Union Radioimmunoassay Market, 2020-2030, USD (Million)
- 9.1. Market Overview
- 9.2. Radioimmunoassay Market: By Product, 2020-2030, USD (Million)
- 9.3. Radioimmunoassay Market: By Application, 2020-2030, USD (Million)
- 9.4. Radioimmunoassay Market: By End User, 2020-2030, USD (Million)
- 9.5.Radioimmunoassay Market: By Region, 2020-2030, USD (Million)
- 9.5.1.UK and European Union
- 9.5.1.1. UK
- 9.5.1.1.1. Radioimmunoassay Market: By Product, 2020-2030, USD (Million)
- 9.5.1.1.1. Radioimmunoassay Market: By Application, 2020-2030, USD (Million)
- 9.5.1.1.1. Radioimmunoassay Market: By End User, 2020-2030, USD (Million)
- 9.5.1.2. Germany
- 9.5.1.2.1. Radioimmunoassay Market: By Product, 2020-2030, USD (Million)
- 9.5.1.2.1. Radioimmunoassay Market: By Application, 2020-2030, USD (Million)
- 9.5.1.2.1. Radioimmunoassay Market: By End User, 2020-2030, USD (Million)
- 9.5.1.3. Spain
- 9.5.1.3.1. Radioimmunoassay Market: By Product, 2020-2030, USD (Million)
- 9.5.1.3.1. Radioimmunoassay Market: By Application, 2020-2030, USD (Million)
- 9.5.1.3.1. Radioimmunoassay Market: By End User, 2020-2030, USD (Million)
- 9.5.1.4. Italy
- 9.5.1.4.1. Radioimmunoassay Market: By Product, 2020-2030, USD (Million)
- 9.5.1.4.1. Radioimmunoassay Market: By Application, 2020-2030, USD (Million)
- 9.5.1.4.1. Radioimmunoassay Market: By End User, 2020-2030, USD (Million)
- 9.5.1.5. France
- 9.5.1.5.1. Radioimmunoassay Market: By Product, 2020-2030, USD (Million)
- 9.5.1.5.1. Radioimmunoassay Market: By Application, 2020-2030, USD (Million)
- 9.5.1.5.1. Radioimmunoassay Market: By End User, 2020-2030, USD (Million)
- 9.5.1.6. Rest of Europe
- 9.5.1.6.1. Radioimmunoassay Market: By Product, 2020-2030, USD (Million)
- 9.5.1.6.1. Radioimmunoassay Market: By Application, 2020-2030, USD (Million)
- 9.5.1.6.1. Radioimmunoassay Market: By End User, 2020-2030, USD (Million)
10. Asia Pacific Radioimmunoassay Market, 2020-2030, USD (Million)
- 10.1. Market Overview
- 10.2. Radioimmunoassay Market: By Product, 2020-2030, USD (Million)
- 10.3. Radioimmunoassay Market: By Application, 2020-2030, USD (Million)
- 10.4. Radioimmunoassay Market: By End User, 2020-2030, USD (Million)
- 10.5.Radioimmunoassay Market: By Region, 2020-2030, USD (Million)
- 10.5.1.Asia Pacific
- 10.5.1.1. China
- 10.5.1.1.1. Radioimmunoassay Market: By Product, 2020-2030, USD (Million)
- 10.5.1.1.1. Radioimmunoassay Market: By Application, 2020-2030, USD (Million)
- 10.5.1.1.1. Radioimmunoassay Market: By End User, 2020-2030, USD (Million)
- 10.5.1.2. Japan
- 10.5.1.2.1. Radioimmunoassay Market: By Product, 2020-2030, USD (Million)
- 10.5.1.2.1. Radioimmunoassay Market: By Application, 2020-2030, USD (Million)
- 10.5.1.2.1. Radioimmunoassay Market: By End User, 2020-2030, USD (Million)
- 10.5.1.3. India
- 10.5.1.3.1. Radioimmunoassay Market: By Product, 2020-2030, USD (Million)
- 10.5.1.3.1. Radioimmunoassay Market: By Application, 2020-2030, USD (Million)
- 10.5.1.3.1. Radioimmunoassay Market: By End User, 2020-2030, USD (Million)
- 10.5.1.4. Australia
- 10.5.1.4.1. Radioimmunoassay Market: By Product, 2020-2030, USD (Million)
- 10.5.1.4.1. Radioimmunoassay Market: By Application, 2020-2030, USD (Million)
- 10.5.1.4.1. Radioimmunoassay Market: By End User, 2020-2030, USD (Million)
- 10.5.1.5. South Korea
- 10.5.1.5.1. Radioimmunoassay Market: By Product, 2020-2030, USD (Million)
- 10.5.1.5.1. Radioimmunoassay Market: By Application, 2020-2030, USD (Million)
- 10.5.1.5.1. Radioimmunoassay Market: By End User, 2020-2030, USD (Million)
- 10.5.1.6. Rest of Asia Pacific
- 10.5.1.6.1. Radioimmunoassay Market: By Product, 2020-2030, USD (Million)
- 10.5.1.6.1. Radioimmunoassay Market: By Application, 2020-2030, USD (Million)
- 10.5.1.6.1. Radioimmunoassay Market: By End User, 2020-2030, USD (Million)
11. Latin America Radioimmunoassay Market, 2020-2030, USD (Million)
- 11.1. Market Overview
- 11.2. Radioimmunoassay Market: By Product, 2020-2030, USD (Million)
- 11.3. Radioimmunoassay Market: By Application, 2020-2030, USD (Million)
- 11.4. Radioimmunoassay Market: By End User, 2020-2030, USD (Million)
- 11.5.Radioimmunoassay Market: By Region, 2020-2030, USD (Million)
- 11.5.1.Latin America
- 11.5.1.1. Brazil
- 11.5.1.1.1. Radioimmunoassay Market: By Product, 2020-2030, USD (Million)
- 11.5.1.1.1. Radioimmunoassay Market: By Application, 2020-2030, USD (Million)
- 11.5.1.1.1. Radioimmunoassay Market: By End User, 2020-2030, USD (Million)
- 11.5.1.2. Mexico
- 11.5.1.2.1. Radioimmunoassay Market: By Product, 2020-2030, USD (Million)
- 11.5.1.2.1. Radioimmunoassay Market: By Application, 2020-2030, USD (Million)
- 11.5.1.2.1. Radioimmunoassay Market: By End User, 2020-2030, USD (Million)
- 11.5.1.3. Rest of Latin America
- 11.5.1.3.1. Radioimmunoassay Market: By Product, 2020-2030, USD (Million)
- 11.5.1.3.1. Radioimmunoassay Market: By Application, 2020-2030, USD (Million)
- 11.5.1.3.1. Radioimmunoassay Market: By End User, 2020-2030, USD (Million)
12. Middle East and Africa Radioimmunoassay Market, 2020-2030, USD (Million)
- 12.1. Market Overview
- 12.2. Radioimmunoassay Market: By Product, 2020-2030, USD (Million)
- 12.3. Radioimmunoassay Market: By Application, 2020-2030, USD (Million)
- 12.4. Radioimmunoassay Market: By End User, 2020-2030, USD (Million)
- 12.5.Radioimmunoassay Market: By Region, 2020-2030, USD (Million)
- 12.5.1.Middle East and Africa
- 12.5.1.1. GCC
- 12.5.1.1.1. Radioimmunoassay Market: By Product, 2020-2030, USD (Million)
- 12.5.1.1.1. Radioimmunoassay Market: By Application, 2020-2030, USD (Million)
- 12.5.1.1.1. Radioimmunoassay Market: By End User, 2020-2030, USD (Million)
- 12.5.1.2. Africa
- 12.5.1.2.1. Radioimmunoassay Market: By Product, 2020-2030, USD (Million)
- 12.5.1.2.1. Radioimmunoassay Market: By Application, 2020-2030, USD (Million)
- 12.5.1.2.1. Radioimmunoassay Market: By End User, 2020-2030, USD (Million)
- 12.5.1.3. Rest of Middle East and Africa
- 12.5.1.3.1. Radioimmunoassay Market: By Product, 2020-2030, USD (Million)
- 12.5.1.3.1. Radioimmunoassay Market: By Application, 2020-2030, USD (Million)
- 12.5.1.3.1. Radioimmunoassay Market: By End User, 2020-2030, USD (Million)
13. Company Profile
- 13.1.
- 13.1.1. Company Overview
- 13.1.2. Financial Performance
- 13.1.3. Product Portfolio
- 13.1.4. Strategic Initiatives
- 13.2. PerkinElmer Inc.
- 13.2.1. Company Overview
- 13.2.2. Financial Performance
- 13.2.3. Product Portfolio
- 13.2.4. Strategic Initiatives
- 13.3. Beckman Coulter, Inc.
- 13.3.1. Company Overview
- 13.3.2. Financial Performance
- 13.3.3. Product Portfolio
- 13.3.4. Strategic Initiatives
- 13.4. DIAsource ImmunoAssays SA
- 13.4.1. Company Overview
- 13.4.2. Financial Performance
- 13.4.3. Product Portfolio
- 13.4.4. Strategic Initiatives
- 13.5. Euro Diagnostica AB
- 13.5.1. Company Overview
- 13.5.2. Financial Performance
- 13.5.3. Product Portfolio
- 13.5.4. Strategic Initiatives
- 13.6. Merck KGaA
- 13.6.1. Company Overview
- 13.6.2. Financial Performance
- 13.6.3. Product Portfolio
- 13.6.4. Strategic Initiatives
- 13.7. MP Biomedicals, LLC
- 13.7.1. Company Overview
- 13.7.2. Financial Performance
- 13.7.3. Product Portfolio
- 13.7.4. Strategic Initiatives
- 13.8. DiaSorin S.p.A.
- 13.8.1. Company Overview
- 13.8.2. Financial Performance
- 13.8.3. Product Portfolio
- 13.8.4. Strategic Initiatives
- 13.9. Berthold Technologies GmbH & Co. KG
- 13.9.1. Company Overview
- 13.9.2. Financial Performance
- 13.9.3. Product Portfolio
- 13.9.4. Strategic Initiatives
- 13.10. DRG International, Inc.
- 13.10.1. Company Overview
- 13.10.2. Financial Performance
- 13.10.3. Product Portfolio
- 13.10.4. Strategic Initiatives
- 13.11. STRATEC Biomedical AG
- 13.11.1. Company Overview
- 13.11.2. Financial Performance
- 13.11.3. Product Portfolio
- 13.11.4. Strategic Initiatives
- 13.12. IBL Internationa
- 13.12.1. Company Overview
- 13.12.2. Financial Performance
- 13.12.3. Product Portfolio
- 13.12.4. Strategic Initiatives
- 13.13. Cisbi
- 13.13.1. Company Overview
- 13.13.2. Financial Performance
- 13.13.3. Product Portfolio
- 13.13.4. Strategic Initiatives
- 13.14. EMD Millipore
- 13.14.1. Company Overview
- 13.14.2. Financial Performance
- 13.14.3. Product Portfolio
- 13.14.4. Strategic Initiatives
- 13.15. Izotop
- 13.15.1. Company Overview
- 13.15.2. Financial Performance
- 13.15.3. Product Portfolio
- 13.15.4. Strategic Initiatives